Nonsteroidal, Nonimmunosuppressive Therapies for Pruritus

Veterinary Clinics of North America - Small Animal Practice

Volumn 43, Issue 1, 2013, Pages 173-187

  Bloom, Paul ^a,b  

^a Allergy Skin and Ear Clinic for Pets ^*  (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Antihistamines; Atopic dermatitis; Barrier dysfunction; Dog; Epidermal lipids; Essential fatty acids; Pruritus; Topical therapy

Indexed keywords

ALIMEMAZINE; AMITRIPTYLINE; ANTIHISTAMINIC AGENT; BETA LACTAM ANTIBIOTIC; BUTORPHANOL; CAPSAICIN; CETIRIZINE; CHLORPHENIRAMINE; CLINDAMYCIN; CYPROHEPTADINE; DIPHENHYDRAMINE; DOXEPIN; ESSENTIAL FATTY ACID; GLUCOCORTICOID; HYDROCORTISONE ACEPONATE; HYDROXYZINE; LIDOCAINE; LORATADINE; MIRTAZAPINE; MISOPROSTOL; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PENTOXIFYLLINE; PRAMOCAINE; PREDNISOLONE; TACROLIMUS; TEMARIL P; THALIDOMIDE; TRIAMCINOLONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIACUTAN PLUS;

ADVERSE OUTCOME; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; ATOPIC DERMATITIS; BACTERIUM COLONY; BATH; COMBINATION CHEMOTHERAPY; CORTICOSTEROID THERAPY; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; EPIDERMAL BARRIER DYSFUNCTION; HOUSE DUST ALLERGY; LOTION; LOW DRUG DOSE; MALASSEZIA PACHYDERMATIS INFECTION; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; PHOTOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SKIN CARE; SKIN DISEASE; SKIN PROTECTION; SKIN PRURITUS; STAPHYLOCOCCAL SKIN INFECTION; SYSTEMIC THERAPY; THERAPY EFFECT; TOPICAL TREATMENT;

ADMINISTRATION, TOPICAL; ANIMALS; CAT DISEASES; CATS; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOG DISEASES; DOGS; FATTY ACIDS, ESSENTIAL; HISTAMINE ANTAGONISTS; PRURITUS; TREATMENT OUTCOME;

CANIS FAMILIARIS;

EID: 84870155600     PISSN: 01955616     EISSN: 18781306     Source Type: Journal    
DOI: 10.1016/j.cvsm.2012.09.001     Document Type: Review

References (67)

1. Savin J.A. How should we define itching?. J Am Acad Dermatol 1998, 38:268-269.
2. Winkelmann R.K., Muller S.A. Pruritus. Annu Rev Med 1964, 15:53-64.
3. Sonkoly E., Muller A., Lauerma A.I., et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006, 117(2):411-417.
4. Steinhoff M., Bienenstock J., Schmelz M., et al. Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus. J Invest Dermatol 2006, 126:1705-1718.
5. Lerner E.A. Chemical mediators of itching. Itch: mechanisms and management of pruritus 1994, 27-36. McGraw-Hill, New York. J.D. Bernhardt (Ed.).
6. Hägermark O. Itch mediators. Semin Dermatol 1995, 14(4):271-276.
7. Hercogová J. Topical anti-itch therapy. Dermatol Ther 2005, 18(4):341-343.
8. Twycross R., Greaves M.W., Handwerker H., et al. Itch: scratching more than the surface. QJM 2003, 96:7-26.
9. Birò T., Ko M.C., Bromm B., et al. How best to fight that nasty itch-from new insights into the neuroimmunological neuroendocrine and neurophysiological bases of pruritus to novel therapeutic approaches. Exp Dermatol 2005, 14:225-240.
10. Yosipovitch G., Dawn A., Greaves M.W. Pathophysiology and clinical aspects of pruritus. Fitzpatrick's dermatology in general medicine 2008, vol. 1:908-911. McGraw-Hill, New York. 7th edition.
11. Scott D.W., Miller W.E., Griffin C.E. Dermatologic therapy. Muller & Kirk's small animal dermatology 2001, 207-273. WB Saunders Company, Philadelphia. 6th edition. D.W. Scott, W.E. Miller, C.E. Griffin (Eds.).
12. Scott D.W., Rothstein E., Miller W.H. A clinical study on the efficacy of two commercial veterinary pramoxine cream rinses in the management of pruritus in atopic dogs. Canine Practice 2000, 25:15-17.
13. Marsella R., Nicklin C.F., Melloy C. The effects of capsaicin topical therapy in dogs with atopic dermatitis: a randomized, double-blinded, placebo-controlled, cross-over clinical trial. Vet Dermatol 2002, 13:131-139.
14. Olivry T., Mueller R.S., The International Task Force On Canine Atopic Dermatitis Evidence-based veterinary dermatology: a systematic review of the pharmacotherapy of canine atopic dermatitis. Vet Dermatol 2003, 14:121-146.
15. Metz M., Grundmann S., Ständer S. Pruritus: an overview of current concepts. Vet Dermatol 2011, 22:121-131.
16. Eschler D.C., Klein P.A. An evidence-based review of the efficacy of topical antihistamines in the relief of pruritus. J Drugs Dermatol 2010, 9(8):992-997.
17. Iwasaki T., Hasegawa A. A randomized comparative clinical trial of recombinant canine interferon-gamma (KT-100) in atopic dogs using antihistamine as control. Vet Dermatol 2006, 17:195-200.
18. Buys L.M. Treatment options for atopic dermatitis. Am Fam Physician 2007, 15(75):523-528.
19. Gottschalk J., Einspanier A., Ungemach F.R., et al. Influence of topical dexamethasone applications on insulin, glucose, thyroid hormone and cortisol levels in dogs. Res Vet Sci 2011, 90:491-497.
20. Behrend EN. Can I diagnose anything with an animal on glucocorticoids? In: ACVIM Proceedings 2003. Available at: Accessed May 14, 2012. http://www.vin.com/Members/Proceedings/Proceedings.plx%3FCID=acvim2003%26PID=pr04114%26O=VIN.
21. Thomas R.C., Logas D., Radosta L., et al. Effects of a 1% hydrocortisone conditioner on haematological and biochemical parameters, adrenal function testing and cutaneous reactivity to histamine in normal and pruritic dogs. Vet Dermatol 1999, 10:109-116.
22. Ständer S., Schürmeyer-Horst F., Luger T.A., et al. Treatment of pruritic diseases with topical calcineurin inhibitors. Ther Clin Risk Manag 2006, 2:213-218.
23. Marsella R., Nicklin C.F., Saglio S., et al. Investigation on the clinical efficacy and safety of 0.1% tacrolimus ointment (protopic) in canine atopic dermatitis: a randomized, double-blinded, placebo controlled, cross-over study. Vet Dermatol 2004, 15:294-303.
24. Bensignor E., Olivry T. Treatment of localized lesions of canine atopic dermatitis with tacrolimus ointment: a blinded randomized controlled trial. Vet Dermatol 2005, 16:52-60.
25. Marsella R. Calcineurin inhibitors: a novel approach to canine atopic dermatitis. J Am Anim Hosp Assoc 2005, 41:92-97.
26. DeBoer D., Marsella R. The ACVD task force on canine atopic dermatitis (XII): the relationship of cutaneous infections to the pathogenesis and clinical course of canine atopic dermatitis. Vet Immunol Immunopathol 2001, 81:239-249.
27. Boguniewicz M., Schmid-Grendelmeier P., Leung D.Y. Atopic dermatitis. J Allergy Clin Immunol 2006, 118:40-43.
28. Ramirez de Knott H.M., McCormick T.S., Kalka K., et al. Cutaneous hypersensitivity to Malassezia sympodialis and dust mite in adult atopic dermatitis with a textile pattern. Contact Dermatitis 2006, 54:92-99.
29. Elias P.M., Hatano Y., Williams M.L. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol 2008, 121:1337-1343.
30. De Benedetto A., Agnihothri R., McGirt L.Y., et al. Atopic dermatitis: a disease caused by innate immune defects?. J Invest Dermatol 2009, 129:14-30.
31. Marsella R., Nicklin C., Lopez J. Studies on the role of various routes of allergen exposure in high IgE producing Beagle dogs sensitized to house dust mites. Vet Dermatol 2006, 17:306-312.
32. Glass E.V., Reid R.A., Hillier A., et al. Use of an amplified ELISA technique for detection of a house dust mite allergen (Derf 1) in the skin and coat dust samples from dogs. Am J Vet Res 2003, 64:162-165.
33. Jackson A.P., Foster A.P., Hart B.J., et al. Prevalence of house dust mites and dermatophagoides group 1 antigens collected from bedding, skin and hair coat of dogs in south-west England. Vet Dermatol 2005, 16:32-38.
34. Randal A., Hillier A., Cole L.K., et al. Quantitation of house dust mite allergens (Der f 1 and group 2) on the skin and hair of dogs. Am J Vet Res 2005, 66:143-149.
35. Loeflath A., von Voigts-Rhetz A., Jaeger K., et al. The use of a whirlpool in topical antipruritic therapy-a double-blinded, randomized, cross-over study. Vet Dermatol 2007 Dec, 18(6):427-431.
36. Reme C.A., Mondon A., Calmon J.P., et al. Efficacy of combined topical therapy with antiallergic shampoo and lotion for the control of signs associated with atopic dermatitis in dogs. Vet Dermatol 2004, 15:S33.
37. Olivry T., DeBoer D.J., Favrot C., et al. Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. Vet Dermatol 2010, 21:233-238.
38. Nojima H., Carstens M.I., Carstens E. c-fos expression in superficial dorsal horn of cervical spinal cord associated with spontaneous scratching in rats with dry skin. Neurosci Lett 2003, 14:62-64.
39. Proksch E., Fölster-Holst R., Jensen J.M. Skin barrier function, epidermal proliferation and differentiation in eczema. J Dermatol Sci 2006, 43(3):159-169.
40. Marsella R., Olivry T., Carlotti D.N., et al. Current evidence of skin barrier dysfunction in human and canine atopic dermatitis. Vet Dermatol 2011, 22:239-248.
41. Novak N., Simon D. Atopic dermatitis-from new pathophysiologic insights to individualized therapy. Allergy 2011, 66:830-839.
42. Reiter L.V., Torres S.M., Wertz P.W. Characterization and quantification of ceramides in the nonlesional skin of canine patients with atopic dermatitis compared with controls. Vet Dermatol 2009, 20:260-266.
43. Shimada K., Yoon J.S., Yoshihara T., et al. Increased transepidermal water loss and decreased ceramide content in lesional and non-lesional skin of dogs with atopic dermatitis. Vet Dermatol 2009, 20:541-546.
44. Kunder C.A., St John A.L., Abraham S.N. Mast cell modulation of the vascular and lymphatic endothelium. Blood 2011, 118:5383-5393.
45. Prussin C., Metcalfe D.D. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2003, 111:S486-S494.
46. Stingl G., Maurer D. IgE-mediated allergen presentation via Fc epsilon RI on antigen-presenting cells. Int Arch Allergy Immunol 1997, 13:24-29.
47. Mudde G.C., van Reijsen F.C., Bruijnzeel-Koomen C.A. Ige-positive Langerhans cells and TH2 allergen-specific T cells in atopic dermatitis. J Invest Dermatol 1992, 99:103S.
48. Ainley-Walker P.F., Patel L., David T.J. Side to side comparison of topical treatment in atopic dermatitis. Arch Dis Child 1998, 79:149-152.
49. Chamlin S.L., Frieden I.J., Fowler A., et al. Ceramide-dominant, barrier-repair lipids improve childhood atopic dermatitis. Arch Dermatol 2001, 137:1110-1112.
50. Chamlin S.L., Kao J., Freiden I.J., et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 2002, 47:198-208.
51. Loden M., Andersson A.C., Lindberg M. Improvement in skin barrier function in patients with atopic dermatitis after treatment with a moisturizing cream (Canoderm). Br J Dermatol 1999, 140:264-267.
52. Hanifin J.M., Hebert A.A., Mays S.R., et al. Effects of a low potency corticosteroid lotion plus a moisturizing regimen in the treatment of atopic dermatitis. Curr Ther Res Clin Exp 1998, 59:227-233.
53. Lucky A.W., Leach A.D., Laskarzewski P., et al. Use of an emollient as a steroid-sparing agent in the treatment of mild to moderate atopic dermatitis in children. Pediatr Dermatol 1997, 14:321-324.
54. Wirén K., Nohlgård C., Nyberg F., et al. Treatment with a barrier-strengthening moisturizing cream delays relapse of atopic dermatitis: a prospective and randomized controlled clinical trial. J Eur Acad Dermatol Venereol 2009, 23:1267-1272.
55. Tretter S., Mueller R.S. The influence of topical unsaturated fatty acids and essential oils on normal and atopic dogs-a pilot study. Vet Dermatol 2010, 21:311-328.
56. Bourdeau P, Bruet V, Gremillet C. Evaluation of phytosphingosine containing shampoo and micro-emulsion spray in the clinical control of allergic dermatosis in dogs: preliminary results of a multicentric study. In: Proceedings from the North American Veterinary Dermatology Forum. Hawaii; April 2007. p. 221.
57. Piekutowska A., Pin D., Rème C.A., et al. Effects of a topically applied preparation of epidermal lipids on the stratum corneum barrier of atopic dogs. J Comp Pathol 2008, 138:197-203.
58. Boguniewicz M., Nicol N., Kelsay K., et al. A multidisciplinary approach to evaluation and treatment of atopic dermatitis. Semin Cutan Med Surg 2008, 27:115-127.
59. Olivry T., Foster A.P., Mueller R.S., et al. Interventions for atopic dermatitis in dogs: a systematic review of randomized controlled trials. Vet Dermatol 2010, 21:4-22.
60. Klein P.A., Clark R.A. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol 1999, 135:1522-1525.
61. Paradis M., Scott D.W., Giroux D. Further investigations on the use of nonsteroidal and steroidal antiinflammatory agents in the management of canine pruritus. J Am Anim Hosp Assoc 1991, 27:44-48.
62. Gupta M., Gupta A. The use of antidepressant drugs in dermatology. J Eur Acad Dermatol Venereol 2001, 15:512-518.
63. Marsella R., Nicklin C.F. Double-blinded cross-over study on the efficacy of pentoxifylline for canine atopy. Vet Dermatol 2000, 11:255-260.
64. Olivry T., Dunston S.M., Rivierre C., et al. A randomized controlled trial of misoprostol monotherapy for canine atopic dermatitis: effects on dermal cellularity and cutaneous tumor necrosis factor-alpha. Vet Dermatol 2003, 14:37-46.
65. Saevik B.K., Bergvall K., Holm B.R., et al. A randomized, controlled study to evaluate the steroid sparing effect of essential fatty acid supplementation in the treatment of canine atopic dermatitis. Vet Dermatol 2004, 15:137-145.
66. Reme C.A., Lloyd D.H., Burrows A., et al. Anti-allergic shampoo and oral essential fatty acid combination therapy to relieve signs of canine atopic dermatitis: a blinded, prednisolone-controlled trial. Vet Dermatol 2003, 14:355.
67. Logas D., Kunkle G.A. Double-blinded crossover study with marine oil supplementation containing high-dose for the treatment of canine pruritic skin disease. Vet Dermatol 1994, 5:99-104.